These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 3946441)

  • 41. Management of prolactinomas: a survey of physicians from the Middle East and North Africa.
    Beshyah SA; Sherif IH; Chentli F; Hamrahian A; Khalil AB; Raef H; El-Fikki M; Jambart S
    Pituitary; 2017 Apr; 20(2):231-240. PubMed ID: 27783196
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Galactorrhea-amenorrhea and hyperprolactinemia associated with pituitary tumors of growth-hormone- and adrenocorticotropic-hormone-secreting cells. A report of two cases.
    Haney AF; McCarty KS; Hammond CB
    J Reprod Med; 1984 Dec; 29(12):883-7. PubMed ID: 6097688
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Amenorrhea-galactorrhea associated with Cushing's disease due to pituitary tumor.
    Rodriguez S; Alger M; Forsbach G; Contreras SN; Canales ES; Zarate A
    J Endocrinol Invest; 1981; 4(1):37-40. PubMed ID: 6263966
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Computed tomography of the brain in patients with serum prolactin levels over 200 ng/ml.
    Chang YC; Liu HM; Huang KM; Wang TC; Hsu JC
    J Formos Med Assoc; 1991 Feb; 90(2):146-52. PubMed ID: 1678408
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The effect of combined estrogen/progestogen treatment in women with hyperprolactinemic amenorrhea.
    Fahy UM; Foster PA; Torode HW; Hartog M; Hull MG
    Gynecol Endocrinol; 1992 Sep; 6(3):183-8. PubMed ID: 1442163
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Amenorrhea, galactorrhea, and hyperprolactinemia.
    Magyar DM
    J Am Osteopath Assoc; 1985 Jun; 85(6):375-80. PubMed ID: 3905728
    [No Abstract]   [Full Text] [Related]  

  • 47. Prolactin-secreting pituitary oncocytoma with galactorrhea--amenorrhea syndrome: a histologic, ultrastructural, and immunocytochemical study.
    Kalyanaraman UP; Halmi NS; Elwood PW
    Cancer; 1980 Oct; 46(7):1584-9. PubMed ID: 7191348
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Features of pituitary tumors and incidentalomas in hyper- and hypoprolactinemia].
    Nag' IuG
    Vopr Onkol; 2008; 54(6):734-8. PubMed ID: 19241849
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Hyperprolactinemia in patients with non-functioning adenoma: analysis of 85 patients treated by transsphenoidal operation].
    Saitoh Y; Mori S; Arita N; Hayakawa T; Mogami H; Oku Y; Onishi T; Uozumi T
    No Shinkei Geka; 1987 Nov; 15(11):1175-9. PubMed ID: 3437926
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Evaluation and treatment of hyperprolactinaemia in women of childbearing age.
    Marek J; Zivný J; Srámková J; Kucera E; Kobilková J
    Acta Univ Palacki Olomuc Fac Med; 1981; 101():110-7. PubMed ID: 6242681
    [No Abstract]   [Full Text] [Related]  

  • 51. [A case of male cystic pituitary adenoma with hyperprolactinemia--clinical study of 6 cases of male prolactinoma].
    Yatsuzuka H; Kitajima T; Taguchi Y; Sakai H; Nakamura N
    No Shinkei Geka; 1986 Dec; 14(13):1601-5. PubMed ID: 3822060
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Coexistent primary empty sella syndrome and hyperprolactinemia. Report of 11 cases.
    Gharib H; Frey HM; Laws ER; Randall RV; Scheithauer BW
    Arch Intern Med; 1983 Jul; 143(7):1383-6. PubMed ID: 6870411
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Headache, hyperprolactinemia, and prolactinomas.
    Strebel PM; Zacur HA; Gold EB
    Obstet Gynecol; 1986 Aug; 68(2):195-9. PubMed ID: 3737035
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Pathologic hyperprolactinemia. I. Positive diagnosis and etiology].
    Vermeulen C; Bouallouche A; Brerault JL; Cathelineau G
    Sem Hop; 1982 Sep; 58(34):1957-71. PubMed ID: 6293080
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Immunocytochemistry of prolactin-producing human pituitary adenomas.
    Duello TM; Halmi NS
    Am J Anat; 1980 Aug; 158(4):463-9. PubMed ID: 7006374
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia.
    Colao A; Di Sarno A; Cappabianca P; Di Somma C; Pivonello R; Lombardi G
    N Engl J Med; 2003 Nov; 349(21):2023-33. PubMed ID: 14627787
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clinical use of metoclopramide test in the diagnosis of women with hyperprolactinemia.
    Vázquez-Matute L; Canales ES; Alger M; Zárate A
    Horm Res; 1979; 10(4):207-12. PubMed ID: 571836
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Hyperprolactinemia: a 12-year retrospective study at gynecologic endocrinology unit, Siriraj Hospital.
    Saejong R; Dangrat C; Techatrisak K; Angsuwatthana S; Rattanachaiyanont M; Tanmahasamut P
    J Med Assoc Thai; 2013 Oct; 96(10):1247-56. PubMed ID: 24350404
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pregnancy-induced changes in prolactinomas as assessed with computed tomography.
    Toffle RC; Webb SM; Tagatz GE; Taylor S; Nagel TC; Campbell B; Phipps W; Okagaki T
    J Reprod Med; 1988 Oct; 33(10):821-6. PubMed ID: 3193413
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Recurrence of hyperprolactinaemia following discontinuation of dopamine agonist therapy in patients with prolactinoma occurs commonly especially in macroprolactinoma.
    Barber TM; Kenkre J; Garnett C; Scott RV; Byrne JV; Wass JA
    Clin Endocrinol (Oxf); 2011 Dec; 75(6):819-24. PubMed ID: 21645021
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.